Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

| More on:
Man pointing at a blue rising share price graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd (ASX: NAN) share price is having a very strong start to the week.

In morning trade, the infection control specialist's shares were up as much as 10% to $3.47.

Why is the Nanosonics share price surging 10%?

Investors have been fighting to get hold of the company's shares on Monday after it released a trading update.

According to the release, Nanosonics delivered strong growth in both capital and consumables/service revenue in the second half compared to the first.

This was particularly the case in the key North America market, which is getting investors excited today.

Management notes that this was driven by additional customer offerings to bridge budget constraints, a number of organisational changes in particular sales territory realignments, and a growing pipeline, together with improvements in sales conversion timelines.

Show me the money

Nanosonics revealed that it expects to report total revenue of approximately $170 million in FY 2024, which is an increase of 2.4% year on year.

This comprises first half revenue of $79.6 million and second half revenue of approximately $90.4 million. The latter represents a half on half increase of 14%.

Nanosonics' second half revenue growth was driven by a 20% half on half increase in capital revenue to $26.4 million and an 11% increase in consumables/service revenue to approximately $64 million.

The company also provided an update on its trophon footprint. It advised that a total of 3,850 trophon units were placed during the year, comprising 2,340 new installed base and 1,510 upgrade units.

For the second half, total units placed were 2,130, up 24% when compared with first half. Whereas new installed base units in the second half were 1,240, which is up 13% half on half. Upgrade unit sales were of 890 for the second half, up 44% on the first half.

The majority of this growth came from North America during the half, with total units placed up 28% to 1,850 and new installed base units up 6% to 1,030.

Nanosonics' CEO and President, Michael Kavanagh, was pleased with the performance. Especially given the challenging trading conditions. He said:

Despite a challenging market environment, the growth opportunity for trophon remains significant. With a growing pipeline for both new installed base and upgrades, it was pleasing to see the sales conversion timelines improve in the second half, which resulted in significant growth in H2 over H1 for capital unit sales.

The Nanosonics share price remains down by almost 30% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »